

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	09/840,2770
Source:	1FW16
Date Processed by STIC:	6/21/04

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 4.2 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
 U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 09/840,277
ATTN: NEW RULES CASES:	PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE
IWrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.
Misaligned Amino Numbering	The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
5Variable Length	Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
6PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
8Skipped Sequences (NEW RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000
9Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
10Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
11Use of <220>	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
Patentin 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
13 Misuse of n/Xaa	"n" can only represent a single <u>nucleotide</u> ; "Xaa" can only represent a single <u>amino acid</u>



IFW16

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/840,277C

DATE: 06/21/2004 TIME: 16:43:13

Input Set : A:\A-688A.ST25.txt

Output Set: N:\CRF4\06212004\1840277C.raw

```
3 <110> APPLICANT: FEIGE, ULRICH
         KOHNO, TADAHIKO
         LACEY, DAVID
         BOONE, THOMAS CHARLES
  8 <120> TITLE OF INVENTION: ADHESION ANTAGONISTS (as amended)
 10 <130> FILE REFERENCE: A-688A
 12 <140> CURRENT APPLICATION NUMBER: US 09/840,277C
 13 <141> CURRENT FILING DATE: 2001-04-23
                                                        pr5-8
 15 <150> PRIOR APPLICATION NUMBER: US 60/198,919
 16 <151> PRIOR FILING DATE: 2000-04-21
 18 <150> PRIOR APPLICATION NUMBER: US 60/201,394
 19 <151> PRIOR FILING DATE: 2000-05-03
 21 <160> NUMBER OF SEQ ID NOS: 137
23 <170> SOFTWARE: PatentIn version 3.2
25 <210> SEQ ID NO: 1
26 <211> LENGTH: 684
27 <212> TYPE: DNA
28 <213> ORGANISM: Homo sapiens
31 <220> FEATURE:
32 <221> NAME/KEY: CDS
33 <222> LOCATION: (1)..(684)
35 <400> SEQUENCE: 1
36 atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc ctg
                                                                          48
37 Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
38 1
                                       10
40 ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc
                                                                         96
41 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
               20
                                   25
44 atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc
                                                                        144
45 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Asp Val Ser
48 cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag
                                                                        192
49 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
                           55
52 gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg
                                                                        240
53 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
                       70
                                           75
56 tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat
                                                                        288
57 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
                   85
60 ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc
                                                                        336
61 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
62
               100
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/840,277C

DATE: 06/21/2004 TIME: 16:43:13

Input Set : A:\A-688A.ST25.txt

Output Set: N:\CRF4\06212004\I840277C.raw

	2+4	~~~															
65	atc	gay	ada	acc	atc	tcc	aaa	gcc	aaa	999	cag	CCC	cga	gaa	cca	cag	384
66	Ile	GIU	пув	THE	тте	ser	ьys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	
		-	115					120					125				
60	gtg	Tac	acc	ctg	- CCC	cca	tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	gtc	432
09	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	
, 0		130					135					140					
/2	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	CCC	agc	gac	atc	gcc	qtq	480
/ 3	ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Āla	Val	
/4	145					150					155					160	
76	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aaq	acc	acq	cct	528
, ,	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	220
78					165					170					175		
80	CCC	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aaσ	ata	acc	576
81	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tvr	Ser	Lvs	Len	Thr	570
82				180		_	_		185			-1-		190	_cu	****	
84	gtg	gac	aag	agc	agg	tgg	caq	caq	aaa	aac	atic	ttc	tra	tac	taa	ata	624
85	Val	Asp	Lys	Ser	Arq	Trp	Gln	Gln	Glv	Asn	Val	Phe	Ser	Cve	Cor	ycy val	624
86		_	195		_	_		200	~- <i>1</i>	11011	vaı	TIIC	205	Cys	ser	val	
88	atg	cat	qaq	act	cta	cac	aac		tac	a.c.c	aaa	330	203	a+ -	.		
89	Met	His	Glu	Ala	Len	His	Agn	Hie	Tur	Thr	Cla	Tara	age	CLC Tarr	CCC	ctg	672
90		210					215	1113	- y -	1111			ser	ьeu	ser	Leu	
	tct		aat.	aaa			213					220					
	Ser																684
	225			Ly S													
	<210	> SE	מד מ	N∩•	2												
	< 2 1	> (rB)	NCTH	'・ つつ	Ω												
				: 22 PPT	8												
99	<212	> TY	PE:	PRT		0 63	nion	a									
99 100	<212) <21	> TY 3> O	PE: RGAN	PRT ISM:	Hom	o sa	pien	ន									
99 100 102	<212) <21 ! <40	> TY 3> O 0> S	PE: RGAN EQUE	PRT ISM: NCE:	Hom 2				Dana		_						
99 100 102 104	<212) <21 ! <40 ! Met	> TY 3> O 0> S	PE: RGAN EQUE	PRT ISM: NCE:	Hom 2				Pro		Pro	Ala	Pro	Glu		Leu	
99 100 102 104 105	<212) <21 ! <40 ! Met ! 1	> TY 3> 0 0> S Asp	PE: RGAN EQUE Lys	PRT ISM: NCE: Thr	Hom 2 His	Thr	Cys	Pro		10					15		
99 100 102 104 105	<212) <21 2 <40 4 Met 5 1 6 Gly	> TY 3> 0 0> S Asp	PE: RGAN EQUE Lys	PRT ISM: NCE: Thr Ser	Hom 2 His	Thr	Cys	Pro	Pro	10				Asp	15		
99 100 102 104 105 108	<212 2 <21 2 <40 4 Met 5 1 6 Gly	> TY 3> O 0> S Asp Gly	PE: RGAN EQUE Lys Pro	PRT ISM: NCE: Thr Ser 20	Hom 2 His 5 Val	Thr Phe	Cys Leu	Pro Phe	Pro 25	10 Pro	Lys	Pro	Lys	Asp	15 Thr	Leu	
99 100 102 104 105 108 109	<212) <21 ! <40 ! Met ; Gly ! Met	> TY 3> O 0> S Asp Gly	PE: RGAN EQUE Lys Pro Ser	PRT ISM: NCE: Thr Ser 20	Hom 2 His 5 Val	Thr Phe	Cys Leu	Pro Phe Val	Pro 25	10 Pro	Lys	Pro	Lys Val	Asp	15 Thr	Leu	
99 100 102 104 105 108 109 112 113	<212) <21 2 <40 4 Met 5 1 6 Gly Met	> TY 3> O 0> S Asp Gly	PE: RGAN EQUE Lys Pro Ser 35	PRT ISM: NCE: Thr Ser 20 Arg	Hom 2 His 5 Val	Thr Phe Pro	Cys Leu Glu	Pro Phe Val 40	Pro 25 Thr	10 Pro Cys	Lys Val	Pro Val	Lys Val	Asp 30 Asp	15 Thr Val	Leu Ser	
99 100 102 104 105 108 109 112 113	<212) <21 ! <40 ! Met ! Gly Met	> TY 3> O 0> S Asp Gly Ile	PE: RGAN EQUE Lys Pro Ser 35	PRT ISM: NCE: Thr Ser 20 Arg	Hom 2 His 5 Val	Thr Phe Pro	Cys Leu Glu Lys	Pro Phe Val 40	Pro 25 Thr	10 Pro Cys	Lys Val	Pro Val Val	Lys Val	Asp 30 Asp	15 Thr Val	Leu Ser	
99 100 102 104 105 108 109 112 113 116	<212) <21 ! <40 ! Met ! Gly ! Met	> TY 3> O 0> S Asp Gly Ile Glu 50	PE: RGAN EQUE Lys Pro Ser 35 Asp	PRT ISM: NCE: Thr Ser 20 Arg	Hom 2 His 5 Val Thr	Thr Phe Pro Val	Cys Leu Glu Lys 55	Pro Phe Val 40 Phe	Pro 25 Thr Asn	10 Pro Cys Trp	Lys Val Tyr	Pro Val Val	Lys Val 45 Asp	Asp 30 Asp Gly	15 Thr Val Val	Leu Ser Glu	
99 100 102 104 105 108 109 112 113 116 117	<212) <21 2 <40 4 Met 5 Gly Met His	> TY 3> O 0> S Asp Gly Ile Glu 50	PE: RGAN EQUE Lys Pro Ser 35 Asp	PRT ISM: NCE: Thr Ser 20 Arg	Hom 2 His 5 Val Thr	Thr Phe Pro Val Thr	Cys Leu Glu Lys 55	Pro Phe Val 40 Phe	Pro 25 Thr Asn	10 Pro Cys Trp	Lys Val Tyr	Pro Val Val	Lys Val 45 Asp	Asp 30 Asp Gly	15 Thr Val Val	Leu Ser Glu	
99 100 102 104 105 108 109 112 113 116 117 120	<212 <21 <40 Met 1 Gly Met His Val	> TY 3> O 0> S Asp Gly Ile Glu 50 His	PE: RGAN EQUE Lys Pro Ser 35 Asp	PRT ISM: NCE: Thr Ser 20 Arg Pro	Hom 2 His 5 Val Thr Glu	Thr Phe Pro Val Thr	Cys Leu Glu Lys 55 Lys	Pro Phe Val 40 Phe Pro	Pro 25 Thr Asn Arg	10 Pro Cys Trp Glu	Lys Val Tyr Glu	Pro Val Val 60 Gln	Lys Val 45 Asp	Asp 30 Asp Gly	15 Thr Val Val Ser	Leu Ser Glu Thr	
99 100 102 104 105 108 109 112 113 116 117 120 121	<pre><212) <21) <40) Met i Gly Met His Val 65 Tyr</pre>	> TY 3> O 0> S Asp Gly Ile Glu 50 His	PE: RGAN EQUE Lys Pro Ser 35 Asp	PRT ISM: NCE: Thr Ser 20 Arg Pro	Hom 2 His 5 Val Thr Glu Lys Ser	Thr Phe Pro Val Thr	Cys Leu Glu Lys 55 Lys	Pro Phe Val 40 Phe Pro	Pro 25 Thr Asn Arg	10 Pro Cys Trp Glu	Lys Val Tyr Glu	Pro Val Val 60 Gln	Lys Val 45 Asp	Asp 30 Asp Gly	15 Thr Val Val Ser	Leu Ser Glu Thr	
99 100 102 104 105 108 109 112 113 116 117 120 121 124 125	<212 <212 <40 Met 51 Gly Met His Val 65 Tyr	> TY 3> O 0> S Asp Gly Ile Glu 50 His	PE: RGAN EQUE Lys Pro Ser 35 Asp Asn Val	PRT ISM: NCE: Thr Ser 20 Arg Pro Ala Val	Hom 2 His 5 Val Thr Glu Lys Ser 85	Thr Phe Pro Val Thr 70 Val	Cys Leu Glu Lys 55 Lys	Pro Phe Val 40 Phe Pro	Pro 25 Thr Asn Arg Val	10 Pro Cys Trp Glu Leu 90	Lys Val Tyr Glu 75 His	Pro Val Val 60 Gln	Lys Val 45 Asp Tyr	Asp 30 Asp Gly Asn Trp	15 Thr Val Val Ser Leu	Leu Ser Glu Thr 80 Asn	
99 100 102 104 105 108 109 112 113 116 117 120 121 124 125 128	<pre><212) <21) <40 !</pre>	> TY 3> O 0> S Asp Gly Ile Glu 50 His	PE: RGAN EQUE Lys Pro Ser 35 Asp Asn Val	PRT ISM: NCE: Thr Ser 20 Arg Pro Ala Val	Hom 2 His 5 Val Thr Glu Lys Ser 85	Thr Phe Pro Val Thr 70 Val	Cys Leu Glu Lys 55 Lys	Pro Phe Val 40 Phe Pro	Pro 25 Thr Asn Arg Val	10 Pro Cys Trp Glu Leu 90	Lys Val Tyr Glu 75 His	Pro Val Val 60 Gln	Lys Val 45 Asp Tyr	Asp 30 Asp Gly Asn Trp	15 Thr Val Val Ser Leu	Leu Ser Glu Thr 80 Asn	
99 100 102 104 105 108 109 112 113 116 117 120 121 124 125 128	<pre><212) <21) <40 !</pre>	> TY 3> O 0> S Asp Gly Ile Glu 50 His Arg	PE: RGAN EQUE Lys Pro Ser 35 Asp Asn Val	PRT ISM: NCE: Thr Ser 20 Arg Pro Ala Val Tyr 100	Hom 2 His 5 Val Thr Glu Lys Ser 85 Lys	Thr Phe Pro Val Thr 70 Val Cys	Cys Leu Glu Lys 55 Lys Leu Lys	Pro Phe Val 40 Phe Pro Thr	Pro 25 Thr Asn Arg Val Ser 105	Trp Glu Leu 90 Asn	Lys Val Tyr Glu 75 His	Pro Val Val 60 Gln Gln Ala	Lys Val 45 Asp Tyr Asp	Asp 30 Asp Gly Asn Trp	Thr Val Val Ser Leu 95 Ala	Leu Ser Glu Thr 80 Asn	
99 100 102 104 105 108 109 112 113 116 117 120 121 124 125 128 129 132	<pre><212) <21) <40 !</pre>	> TY 3> O 0> S Asp Gly Ile Glu 50 His Arg	PE: RGAN EQUE Lys Pro Ser 35 Asp Asn Val	PRT ISM: NCE: Thr Ser 20 Arg Pro Ala Val Tyr 100	Hom 2 His 5 Val Thr Glu Lys Ser 85 Lys	Thr Phe Pro Val Thr 70 Val Cys	Cys Leu Glu Lys 55 Lys Leu Lys	Pro Phe Val 40 Phe Pro Thr	Pro 25 Thr Asn Arg Val Ser 105	Trp Glu Leu 90 Asn	Lys Val Tyr Glu 75 His	Pro Val Val 60 Gln Gln Ala	Lys Val 45 Asp Tyr Asp	Asp 30 Asp Gly Asn Trp	Thr Val Val Ser Leu 95 Ala	Leu Ser Glu Thr 80 Asn	
99 100 102 104 105 108 109 112 113 116 117 120 121 124 125 128 129 132	<pre><212) <21) <40 ! <40 ! Met if I ! Gly Met His Val 65 Tyr Gly Ile</pre>	> TY 3> O 0> S Asp Gly Ile Glu 50 His Arg Lys	PE: RGAN EQUE Lys Pro Ser 35 Asp Asn Val Glu Lys 115	PRT ISM: NCE: Thr Ser 20 Arg Pro Ala Val Tyr 100 Thr	Hom 2 His 5 Val Thr Glu Lys Ser 85 Lys	Thr Phe Pro Val Thr 70 Val Cys Ser	Cys Leu Glu Lys 55 Lys Leu Lys	Pro Phe Val 40 Phe Pro Thr Val Ala 120	Pro 25 Thr Asn Arg Val Ser 105 Lys	Trp Glu Leu 90 Asn	Lys Val Tyr Glu 75 His Lys	Pro Val Val 60 Gln Gln Ala Pro	Lys Val 45 Asp Tyr Asp Leu Arg	Asp 30 Asp Gly Asn Trp Pro 110 Glu	15 Thr Val Val Ser Leu 95 Ala	Leu Ser Glu Thr 80 Asn Pro	
99 100 102 104 105 108 109 112 113 116 117 120 121 124 125 128 129 132 133 136	<pre><212) <21) <40 ! <40 ! Met if I ! Gly Met His Val Gly Ile Val</pre>	> TY 3> O 0> S Asp Gly Ile Glu 50 His Arg Lys	PE: RGAN EQUE Lys Pro Ser 35 Asp Asn Val Glu Lys 115	PRT ISM: NCE: Thr Ser 20 Arg Pro Ala Val Tyr 100 Thr	Hom 2 His 5 Val Thr Glu Lys Ser 85 Lys	Thr Phe Pro Val Thr 70 Val Cys Ser	Cys Leu Glu Lys 55 Lys Leu Lys	Pro Phe Val 40 Phe Pro Thr Val Ala 120	Pro 25 Thr Asn Arg Val Ser 105 Lys	Trp Glu Leu 90 Asn	Lys Val Tyr Glu 75 His Lys	Pro Val Val 60 Gln Gln Ala Pro	Lys Val 45 Asp Tyr Asp Leu Arg	Asp 30 Asp Gly Asn Trp Pro 110 Glu	15 Thr Val Val Ser Leu 95 Ala	Leu Ser Glu Thr 80 Asn Pro	
99 100 102 104 105 108 109 112 113 116 117 120 121 124 125 128 129 132 133 136 137	<pre><212) <21) <40 ! <40 ! Met if I ! Gly Met His Val Gly Ile Val Val Val Val Val Val Val V</pre>	> TY 3> O 0> S Asp Gly Ile Glu 50 His Arg Lys Glu Tyr 130	PE: RGAN EQUE Lys Pro Ser 35 Asp Asn Val Glu Lys 115 Thr	PRT ISM: NCE: Thr Ser 20 Arg Pro Ala Val Tyr 100 Thr Leu	Hom 2 His 5 Val Thr Glu Lys Ser 85 Lys Ile	Thr Phe Pro Val Thr 70 Val Cys Ser	Cys Leu Glu Lys 55 Lys Leu Lys Ser 135	Pro Phe Val 40 Phe Pro Thr Val Ala 120 Arg	Pro 25 Thr Asn Arg Val Ser 105 Lys	Trp Glu Leu 90 Asn Gly Glu	Lys Val Tyr Glu 75 His Lys Gln Leu	Pro Val Val 60 Gln Gln Ala Pro Thr 140	Lys Val 45 Asp Tyr Asp Leu Arg 125 Lys	Asp 30 Asp Gly Asn Trp Pro 110 Glu Asn	Thr Val Val Ser Leu 95 Ala Pro Gln	Leu Ser Glu Thr 80 Asn Pro Gln Val	
99 100 102 104 105 108 109 112 113 116 117 120 121 124 125 128 129 132 133 136 137	<pre><212) <21) <40 ! <40 ! Met if I ! Gly Met His Val Gly Ile Val Val Val Val Val Val Val V</pre>	> TY 3> O 0> S Asp Gly Ile Glu 50 His Arg Lys Glu Tyr 130	PE: RGAN EQUE Lys Pro Ser 35 Asp Asn Val Glu Lys 115 Thr	PRT ISM: NCE: Thr Ser 20 Arg Pro Ala Val Tyr 100 Thr Leu	Hom 2 His 5 Val Thr Glu Lys Ser 85 Lys Ile	Thr Phe Pro Val Thr 70 Val Cys Ser	Cys Leu Glu Lys 55 Lys Leu Lys Ser 135	Pro Phe Val 40 Phe Pro Thr Val Ala 120 Arg	Pro 25 Thr Asn Arg Val Ser 105 Lys	Trp Glu Leu 90 Asn Gly Glu	Lys Val Tyr Glu 75 His Lys Gln Leu	Pro Val Val 60 Gln Gln Ala Pro Thr 140	Lys Val 45 Asp Tyr Asp Leu Arg 125 Lys	Asp 30 Asp Gly Asn Trp Pro 110 Glu Asn	Thr Val Val Ser Leu 95 Ala Pro Gln	Leu Ser Glu Thr 80 Asn Pro Gln Val	
99 100 102 104 105 108 109 112 113 116 117 120 121 124 125 128 129 132 133 136 137 140	<pre><212) <21) <40 ! <40 ! Met if I ! Gly Met His Val Gly Ile Val</pre>	> TY 3> O 0> S Asp Gly Ile Glu 50 His Arg Lys Glu Tyr 130	PE: RGAN EQUE Lys Pro Ser 35 Asp Asn Val Glu Lys 115 Thr	PRT ISM: NCE: Thr Ser 20 Arg Pro Ala Val Tyr 100 Thr Leu	Hom 2 His 5 Val Thr Glu Lys Ser 85 Lys Ile	Thr Phe Pro Val Thr 70 Val Cys Ser	Cys Leu Glu Lys 55 Lys Leu Lys Ser 135	Pro Phe Val 40 Phe Pro Thr Val Ala 120 Arg	Pro 25 Thr Asn Arg Val Ser 105 Lys	Trp Glu Leu 90 Asn Gly Glu	Lys Val Tyr Glu 75 His Lys Gln Leu	Pro Val Val 60 Gln Gln Ala Pro Thr 140	Lys Val 45 Asp Tyr Asp Leu Arg 125 Lys	Asp 30 Asp Gly Asn Trp Pro 110 Glu Asn	Thr Val Val Ser Leu 95 Ala Pro Gln	Leu Ser Glu Thr 80 Asn Pro Gln Val	

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/840,277C

DATE: 06/21/2004 TIME: 16:43:13

Input Set : A:\A-688A.ST25.txt

Output Set: N:\CRF4\06212004\1840277C.raw

144 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 145 165 148 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 152 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 156 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 157 210 160 Ser Pro Gly Lys 161 225 164 <210> SEQ ID NO: 3 165 <211> LENGTH: 8 166 <212> TYPE: PRT 167 <213> ORGANISM: Artificial Sequence 169 <220> FEATURE: 170 <223> OTHER INFORMATION: Preferred linker 172 <400> SEQUENCE: 3 174 Gly Gly Gly Lys Gly Gly Gly 175 1 178 <210> SEQ ID NO: 4 179 <211> LENGTH: 8 180 <212> TYPE: PRT 181 <213> ORGANISM: Artificial Sequence 183 <220> FEATURE: 184 <223> OTHER INFORMATION: Preferred linker 186 <400> SEQUENCE: 4 188 Gly Gly Gly Asn Gly Ser Gly Gly 189 1 192 <210> SEQ ID NO: 5 193 <211> LENGTH: 8 194 <212> TYPE: PRT 195 <213> ORGANISM: Artificial Sequence 197 <220> FEATURE: 198 <223> OTHER INFORMATION: Preferred linker 200 <400> SEQUENCE: 5 202 Gly Gly Gly Cys Gly Gly Gly 203 1 206 <210> SEQ ID NO: 6 207 <211> LENGTH: 5 208 <212> TYPE: PRT 209 <213> ORGANISM: Artificial Sequence 211 <220> FEATURE: 212 <223> OTHER INFORMATION: Preferred linker 214 <400> SEQUENCE: 6 216 Gly Pro Asn Gly Gly 217 1 220 <210> SEQ ID NO: 7 221 <211> LENGTH: 5 222 <212> TYPE: PRT

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/840,277C

DATE: 06/21/2004 TIME: 16:43:13

Input Set : A:\A-688A.ST25.txt

Output Set: N:\CRF4\06212004\1840277C.raw

```
223 <213> ORGANISM: Artificial Sequence
      225 <220> FEATURE:
      226 <223> OTHER INFORMATION: Laminin peptide
      228 <400> SEQUENCE: 7
      230 Tyr Ile Gly Ser Arg
      231 1
      234 <210> SEQ ID NO: 8
      235 <211> LENGTH: 49
      236 <212> TYPE: PRT
      237 <213> ORGANISM: Artificial Sequence
      239 <220> FEATURE:
      240 <223> OTHER INFORMATION: Echistatin peptide
      242 <400> SEQUENCE: 8
      244 Glu Cys Glu Ser Gly Pro Cys Cys Arg Asn Cys Lys Phe Leu Lys Glu
      245 1
      248 Gly Thr Ile Cys Lys Arg Ala Arg Gly Asp Asp Met Asp Asp Tyr Cys
                      20
      252 Asn Gly Lys Thr Cys Asp Cys Pro Arg Asn Pro His Lys Gly Pro Ala
      253
                  35
      256 Thr
      260 <210> SEQ ID NO: 9
      261 <211> LENGTH: 7
      262 <212> TYPE: PRT
      263 <213> ORGANISM: Artificial Sequence
      265 <220> FEATURE:
     266 <223> OTHER INFORMATION: RGD, NGR derivative peptide
     269 <220> FEATURE:
     270 <221> NAME/KEY: misc_feature
     271 <222> LOCATION: (2, 5 and)..(7)
     272 <223> OTHER INFORMATION: Xaa is any amino acid
     274 <400> SEQUENCE: 9
W--> 276 Arg Xaa Glu Thr Xaa Trp Xaa
     277 1
     280 <210> SEQ ID NO: 10
     282 <400> SEQUENCE: 10
W--> 283 000
     285 <210> SEQ ID NO: 11
     286 <211> LENGTH: 9
     287 <212> TYPE: PRT
     288 <213> ORGANISM: Artificial Sequence
     290 <220> FEATURE:
     291 <223> OTHER INFORMATION: RGD, NGR derivative peptide
     294 <220> FEATURE:
     295 <221> NAME/KEY: misc_feature
     296 <222> LOCATION: (2, 3, 7 and)..(8)
     297 <223> OTHER INFORMATION: Xaa is any amino acid
     299 <400> SEQUENCE: 11
W--> 301 Cys Xaa Xaa Arg Leu Asp Xaa Xaa Cys
     302 1
```

5

DATE: 06/21/2004

PATENT APPLICATION: US/09/840,277C TIME: 16:43:13 Input Set : A:\A-688A.ST25.txt Output Set: N:\CRF4\06212004\1840277C.raw 305 <210> SEQ ID NO: 12 307 <400> SEQUENCE: 12 W--> 308 000 310 <210> SEQ ID NO: 13 311 <211> LENGTH: 9 312 <212> TYPE: PRT 313 <213> ORGANISM: Artificial Sequence 315 <220> FEATURE: 316 <223> OTHER INFORMATION: RGD, NGR derivative peptide 319 <220> FEATURE: 320 <221> NAME/KEY: misc_feature 321 <222> LOCATION: (1, 2, 3, 7, 8 and)..(9) 322 <223> OTHER INFORMATION: Xaa is any amino acid with Xaa at 1, 3, 7 and 9 capable of forming a bridge. 325 <400> SEQUENCE: 13 W--> 327 Xaa Xaa Xaa Arg Gly Asp Xaa Xaa Xaa 328 1 331 <210> SEQ ID NO: 14 332 <211> LENGTH: 17 333 <212> TYPE: PRT 334 <213> ORGANISM: Artificial Sequence 336 <220> FEATURE: 337 <223> OTHER INFORMATION: RGD, NGR derivative peptide 340 <220> FEATURE: 341 <221> NAME/KEY: misc_feature 342 <222> LOCATION: $(2, \frac{3}{3}, 4, 5, 6, 12, 13, 14, 15 \text{ and})$..(16) 343 <223> OTHER INFORMATION: At positions 2, 3, 4, 5, 6, 12, 13, 14, 15 and 16, Xaa is any amino acid or may be absent. 346 <400> SEQUENCE: 14 W--> 348 Cys Xaa Xaa Xaa Xaa Cys Arg Gly Asp Cys Xaa Xaa Xaa Xaa 349 1 5 352 Cys 356 <210> SEQ ID NO: 15 357 <211> LENGTH: 8 358 <212> TYPE: PRT 359 <213> ORGANISM: Artificial Sequence 361 <220> FEATURE: 362 <223> OTHER INFORMATION: RGD, NGR derivative peptide 365 <220> FEATURE: 366 <221> NAME/KEY: misc_feature 367 <222> LOCATION: (1 and)..(8) 368 <223> OTHER INFORMATION: Xaa is an independently selected amino acid. 370 <220> FEATURE: 371 <221> NAME/KEY: misc_feature 372 <222> LOCATION: (2 and)..(7) 373 <223> OTHER INFORMATION: Xaa equals 0 to 4 amino acids, each which is independently Sheet. 370 <220> FEATURE:

RAW SEQUENCE LISTING

376 <220> FEATURE:

selected.

377 <221> NAME/KEY: misc_feature

SP is at location 4 <222> LOCATION: (4) ... (4)<223> OTHER INFORMATION: Xaa is selected from the group consisting of glycine and leucine. <220> FEATURE: what about Xaa at levation 6? <221> NAME/KEY: misc_feature <222> LOCATION: (5)..(5) <223> OTHER INFORMATION: Xaa is selected from the group consisting of tryptophan and leucine. <400> SEQUENCE: 15

Xaa Xaa Asp Asp Xaa Xaa Xaa

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/840,277C

DATE: 06/21/2004 TIME: 16:43:14

Input Set : A:\A-688A.ST25.txt

Output Set: N:\CRF4\06212004\1840277C.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:9; Xaa Pos. 2,5,7 Seq#:11; Xaa Pos. 2,3,7,8 Seq#:13; Xaa Pos. 1,2,3,7,8,9 Seq#:14; Xaa Pos. 2,3,4,5,6,12,13,14,15,16 Seq#:15; Xaa Pos. 1,2,8,6,7,8 Seq#:16; Xaa Pos. 1,2,3,6,7,8,9,10 Seq#:17; Xaa Pos. 3,5,6,13,15 Seq#:18; Xaa Pos. 2,3,4,7,15 Seq#:19; Xaa Pos. 3,4,5,6,8,13,15,18 Seq#:20; Xaa Pos. 2,5,6,7,12,13,14 Seq#:21; Xaa Pos. 1,3,6,9,12,13 Seq#:40; Xaa Pos. 3,4 Seq#:50; Xaa Pos. 2,3 Seq#:58; Xaa Pos. 5 Seq#:59; Xaa Pos. 6 Seq#:86; Xaa Pos. 3,15 Seq#:87; Xaa Pos. 13,15



VERIFICATION SUMMARY

PATENT APPLICATION: US/09/840,277C

DATE: 06/21/2004 TIME: 16:43:14

Input Set : A:\A-688A.ST25.txt

Output Set: N:\CRF4\06212004\1840277C.raw

```
L:276 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0
L:283 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (10) SEQUENCE:
L:301 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:0
L:308 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (12) SEQUENCE:
L:327 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13 after pos.:0
L:348 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14 after pos.:0
L:389 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15 after pos.:0
L:437 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16 after pos.:0
L:457 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17 after pos.:0
L:481\ M:341\ W: (46) "n" or "Xaa" used, for SEQ ID#:18 after pos.:0
L:501 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19 after pos.:0
M:341 Repeated in SeqNo=19
L:525 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20 after pos.:0
L:545 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21 after pos.:0
L:817 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:40 after pos.:0
L:963 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50 after pos.:0
L:1109 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:58 after pos.:0
L:1129 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:59 after pos.:0
L:1525 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:86 after pos.:0
L:1545 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:87 after pos.:0
```